Takeda Pharmaceutical downgraded by Morgan Stanley
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley downgraded Takeda Pharmaceutical from Overweight to Equal-Weight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/16/2023 | $20.00 | Neutral → Buy | BofA Securities |
| 7/19/2022 | $21.00 → $24.00 | Market Perform → Outperform | Cowen |
| 10/7/2021 | Overweight → Equal-Weight | Morgan Stanley |
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational Efficiencies First Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 Takeda ((4502, NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: "Takeda's fiscal year 2025 first half
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.Innovent will grant Takeda exclusive ri
– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care – Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Takeda ((TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), du
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational Efficiencies First Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 Takeda ((4502, NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: "Takeda's fiscal year 2025 first half
Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the HYQVIA Infusion1,2 HyHub and HyHub Duo Represent Takeda's First Devices Customized for Use with a Plasma-Derived Therapy to Help Address Unmet Patient Needs Takeda ((TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are prescribed HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]. The dedicated devices allow HYQVIA, a facilitated subcu
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.Innovent will grant Takeda exclusive ri
− Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEO Takeda ((TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division. This press r
Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry. Mos
Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave
3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight
BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00
Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously